Ceftaroline fosamil

DRUG15 trials

Sponsors

Assistance Publique Hopitaux De Paris, Friedrich-Schiller-Universitaet Jena, Forest Laboratories, Pfizer, Baylor College of Medicine

Conditions

Bone InfectionCatheter related bloodstream infections due to Staphylococcus aureusCommunity Acquired PneumoniaCommunity-Acquired Bacterial Pneumonia (CABP)Complicated Skin and Soft Tissue InfectionHematogenously Acquired Staphylococcus Aureus OsteomyelitisInfectionsInfections, Pediatrics

Phase 1

Ceftaroline for Treatment of Hematogenously Acquired Staphylococcus Aureus Osteomyelitis in Children

CompletedNCT02335905

Baylor College of MedicineBone Infection, Hematogenously Acquired Staphylococcus Aureus Osteomyelitis, Osteomyelitis

Start: 2015-06-03End: 2020-06-16Updated: 2021-11-02

Penetration of Ceftaroline Into Cerebrospinal Fluid(CSF)

CompletedNCT02806882

Centre Hospitalier Universitaire DijonMeningitis, Ventriculitis

Start: 2015-04-29End: 2016-10-24Updated: 2024-02-21

Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection

Enrolling by invitationNCT07228702

Vancouver Coastal HealthMycobacterium Abscessus Infection, Non-Tuberculous Mycobacterial (NTM) Pneumonia

Start: 2026-01-11End: 2027-10-01Target: 1Updated: 2026-06-03

Phase 2

Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Skin Infections

CompletedNCT01400867

Forest LaboratoriesInfections, Pediatrics

Start: 2011-12-31End: 2014-07-31Updated: 2015-01-13

Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Community Acquired Bacterial Pneumonia (CABP)

CompletedNCT01530763

Forest LaboratoriesCommunity Acquired Pneumonia, Infections

Start: 2012-09-30End: 2014-07-31Updated: 2015-01-13

Safety, Tolerability and Efficacy of Ceftaroline in Paediatrics With Late-Onset Sepsis

TerminatedNCT02424734

PfizerLate-onset Sepsis

Start: 2015-08-04End: 2017-12-26Updated: 2018-09-13

Phase 3

Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections

CompletedNCT01499277

PfizerComplicated Skin and Soft Tissue Infection

Start: 2012-05-31End: 2015-01-31Updated: 2017-09-06

Evaluation of Ceftaroline Fosamil vs Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections.

TerminatedNCT02202135

PfizerComplicated Skin and Soft Tissue Infection

Start: 2014-06-30End: 2015-01-31Updated: 2017-09-06

Randomized open-label controlled trial evaluating a single-dose intravenous Dalbavancin versus standard antibiotic therapy during catheterrelated bloodstream infections due to Staphylococcus aureus [DALICATH]

RecruitingCTIS2024-514952-34-00

Assistance Publique Hopitaux De ParisCatheter related bloodstream infections due to Staphylococcus aureus

Start: 2023-06-23Target: 406Updated: 2025-04-23

Efficacy and safety of Dalbavancin in the treatment of infective Endocarditis caused by gram-positive cocci

Not yet recruitingCTIS2026-526149-91-00

Friedrich-Schiller-Universitaet Jenaenterococci, Infectious endocarditis caused by Gram-positive cocci (staphylococci, streptococci)

Target: 166Updated: 2026-06-30

Phase 4

Study of Blood Levels of Ceftaroline Fosamil in Children Who Are Receiving Antibiotic Therapy in the Hospital

CompletedNCT01298843

Forest LaboratoriesInfections

Start: 2011-04-30End: 2013-02-28Updated: 2014-05-14

Evaluation of Ceftaroline Fosamil Versus a Comparator in Adult Subjects With Community-acquired Bacterial Pneumonia (CABP) With Risk for Methicillin-resistant Staphylococcus Aureus

CompletedNCT01645735

Forest LaboratoriesInfections

Start: 2012-10-31End: 2013-12-31Updated: 2016-02-01

Safety and Efficacy Study of Ceftaroline in Elderly Subjects With Community-Acquired Bacterial Pneumonia

WithdrawnNCT01666743

Forest LaboratoriesCommunity-Acquired Bacterial Pneumonia (CABP)

Start: 2012-11-30End: 2014-03-31Updated: 2013-02-11

Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Community Acquired Pneumonia (CABP)

CompletedNCT01669980

Forest LaboratoriesInfections, Pneumonia

Start: 2012-10-31End: 2014-08-31Updated: 2015-11-02

Safety and Efficacy Study of Ceftaroline in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia

CompletedNCT01701219

Forest LaboratoriesMethicillin-resistant Staphylococcus Aureus (MRSA) Bacteremia, Staphylococcus Aureus Bacteremia

Start: 2013-01-31End: 2014-07-31Updated: 2014-07-31

Related Papers

Treatment outcomes of secondary bacteraemia in patients treated with ceftaroline fosamil: pooled results from six phase III clinical trials.

2021-12-162 citations

Impact of Underlying Comorbidities on Outcomes of Patients Treated with Ceftaroline Fosamil for Complicated Skin and Soft Tissue Infections: Pooled Results from Three Phase III Randomized Clinical Trials.

2021-11-063 citations

Baseline Characteristics and Outcomes Among Patients with Complicated Skin and Soft Tissue Infections Admitted to the Intensive Care Unit: Analysis of the Phase 3 COVERS Randomized Trial of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam.

2020-06-302 citations

Phase 2 Study of the Safety, Pharmacokinetics and Efficacy of Ceftaroline Fosamil in Neonates and Very Young Infants With Late-onset Sepsis

The Pediatric Infectious Disease Journal2020-02-2126 citations

Summary of the safety and tolerability of two treatment regimens of ceftaroline fosamil: 600 mg every 8 h versus 600 mg every 12 h.

2019-04-0111 citations

Ceftaroline fosamil therapy in patients with acute bacterial skin and skin-structure infections with systemic inflammatory signs: A retrospective dose comparison across three pivotal trials

International Journal of Antimicrobial Agents2019-02-016 citations

A Phase III, randomized, controlled, non-inferiority trial of ceftaroline fosamil 600 mg every 8 h versus vancomycin plus aztreonam in patients with complicated skin and soft tissue infection with systemic inflammatory response or underlying comorbidities.

2016-09-0148 citations

A Multicenter, Randomized, Observer-blinded, Active-controlled Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Comparator in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infection.

2016-08-0134 citations

A Randomized, Prospective Study of Pediatric Patients With Community-acquired Pneumonia Treated With Ceftaroline Versus Ceftriaxone.

2016-07-0134 citations

A Multicenter, Randomized, Observer-blinded, Active-controlled Study Evaluating the Safety and Effectiveness of Ceftaroline Compared With Ceftriaxone Plus Vancomycin in Pediatric Patients With Complicated Community-acquired Bacterial Pneumonia.

2016-07-0132 citations